fiscal year. (vi) The number of individuals receiving such drug under the program in the preceding fiscal year. (vii) Average spending on the drug per beneficiary for the preceding fiscal year. (viii) With respect to a drug covered under part B of such title XVIII the average sales price as determined under section 1847A of the Social Security Act ( 42 U.S.C. 1395w–3a ) for the preceding fiscal year. (ix) Consumer-friendly information about the average, highest, and lowest out-of-pocket cost for the drug (such as copayment or coinsurance amounts) for an individual enrolled in a State plan under such title XIX or the Medicare program under such title XVIII (including parts B and D of such title) in the preceding fiscal year or in the preceding plan year in the case of part D of such title, including such costs under such part before, during, and after the coverage gap described in subparagraphs (C) and (D) section 1860D–2(b)(2) of the Social Security Act ( 42 U.S.C. 1395w–102(b)(2) ). (x) Such additional information pertaining to Federal expenditures on, or consumer out-of-pocket costs for, drugs, as the Secretary determines appropriate. (2) Highlighted drugs The Secretary shall identify, in a separate element of the dashboard— (A) for each Federal program described in paragraph (1)(D), the 15 drugs with the highest total program spending, including, for drugs covered under the Medicaid program, the median State spending per dosage unit